focus -WSS

focus

author：comprehensive 2025-10-01 23:59:10 - browse：4

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： At JPM 2024, hospital systems pitch financial strength to investors

WSS

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

What we’ve learned from the Aduhelm mess

Allen Institute goes after foundational questions, CEO Costa says

The Readout: Gilead, Bernie Sanders, and other pharma news

Profiling embryos to choose those with higher IQs is almost a reality

Gilead might be held responsible for not developing a drug

leisure time

focus

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

The Readout: Gilead, Bernie Sanders, and other pharma news

Continuity nursing helped my family in our darkest PICU moments

Industry veterans launch new biotech VC with $310M

In age of alternative facts, a scholarly course on calling out crap

What should King Charles tell the public about his cancer?

Medical leaders decry Supreme Court decision on affirmative action

The dental labor crisis is a moment of opportunity

As demand for Covid shots wanes, Moderna seeks its next success

Robert F. Kennedy is pitching centrism on health, even on abortion

focus

Medicare Advantage coverage denials need scrutiny, senators say

How digital tools helped lower hypertension in marginalized patients

How digital tools helped lower hypertension in marginalized patients

Does Paxlovid work in people vaccinated against Covid

How digital tools helped lower hypertension in marginalized patients

Ascension's ugly legal battle over care for poor patients in Texas

Wikipedia

focus

leisure time

leisure time